GPR54 regulates non-small cell lung cancer development via dopa decarboxylase
Summary
Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is a leading cause of cancer death. G protein-coupled receptor 54 (GPR54) plays a role in cancer development by interacting with its endogenous ligand kisspeptin encoded by the KISS1 gene. However, the role of GPR54 in NSCLC development is not yet fully understood. Here, we demonstrate that GPR54 regulates NSCLC development via dopa decarboxylase (DDC). A mutant Kras-driven mouse lung cancer model revealed that adenov
Content
# GPR54 regulates non-small cell lung cancer development via dopa decarboxylase
*Published: 2026 Mar 2*
Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is a
leading cause of cancer death. G protein-coupled receptor 54 (GPR54) plays a
role in cancer development by interacting with its endogenous ligand kisspeptin
encoded by the KISS1 gene. However, the role of GPR54 in NSCLC development is
not yet fully understood. Here, we demonstrate that GPR54 regulates NSCLC
development via dopa decarboxylase (DDC). A mutant Kras-driven mouse lung cancer
model revealed that adenoviral CMV-Cre-mediated Gpr54 deletion attenuated NSCLC
development. Both Gpr54 deletion in mouse NSCLC tissues and GPR54 knockdown in
human NSCLC cell lines caused apoptotic cell death. In addition, GPR54
regulation of NSCLC cell proliferation involves both the Gαq/11/AKT and
β-arrestin/ERK signaling pathways. RNA sequencing revealed that Gpr54 deletion
altered a gene set related to glycolysis and genotype-dependently regulated Ddc
gene expression. Moreover, the regulation of glycolysis and DDC expression by
GPR54 was dependent on the Gαq/11/PI3K/AKT/mTOR signaling pathway.
Phosphoprotein arrays further revealed that DDC regulated NF-κB phosphorylation
in NSCLC cells. Consistently, DDC regulated both NSCLC cell proliferation in
vitro and tumor growth in vivo. Overall, our findings suggest that GPR54 could
be a diagnostic marker for NSCLC and that therapeutics targeting GPR54 signaling
may be useful for treating NSCLC.
DOI: 10.1038/s41392-026-02591-x